» Articles » PMID: 22496917

Role of MiR-148a in Hepatitis B Associated Hepatocellular Carcinoma

Overview
Journal PLoS One
Date 2012 Apr 13
PMID 22496917
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatitis B virus encoded X antigen (HBx) is a trans-regulatory protein that alters the activity of selected transcription factors and cytoplasmic signal transduction pathways. HBx transcriptionally up-regulates the expression of a unique gene, URG11, which in turn transcriptionally up-regulates β-catenin, thereby contributing importantly to hepatocarcinogenesis. HBx and URG11 also alter the expression of multiple microRNAs, and by miRNA array analysis, both were shown to promote the expression of miR-148a. Elevated miR-148a was also seen in HBx positive liver samples from infected patients. To study the function of miR-148a, anti-148a was introduced into HepG2 and Hep3B cells stably expressing HBx or stably over-expressing URG11. Anti-miR-148a suppressed cell proliferation, cell cycle progression, cell migration, anchorage independent growth in soft agar and subcutaneous tumor formation in SCID mice. Introduction of anti-miR-148a increased PTEN protein and mRNA expression, suggesting that PTEN was targeted by miR-148a. Anti-miR-148a failed to suppress PTEN expression when co-transfected with reporter gene mutants in the 3'UTR of PTEN mRNA. Introduction of anti-miR-148a also resulted in depressed Akt signaling by HBx and URG11, resulting in decreased expression of β-catenin. Thus, miR-148a may play a central role in HBx/URG11 mediated HCC, and may be an early diagnostic marker and/or therapeutic target associated with this tumor type.

Citing Articles

Dysregulated microRNAs as a biomarker for diagnosis and prognosis of hepatitis B virus-associated hepatocellular carcinoma.

Zhang M, Yuan Y, Liu L, Wei Y, Yin W, Zheng L World J Gastroenterol. 2023; 29(31):4706-4735.

PMID: 37664153 PMC: 10473924. DOI: 10.3748/wjg.v29.i31.4706.


Exosome-depleted MiR-148a-3p derived from Hepatic Stellate Cells Promotes Tumor Progression via ITGA5/PI3K/Akt Axis in Hepatocellular Carcinoma.

Zhang X, Chen F, Huang P, Wang X, Zhou K, Zhou C Int J Biol Sci. 2022; 18(6):2249-2260.

PMID: 35414782 PMC: 8990464. DOI: 10.7150/ijbs.66184.


Diagnostic value of microRNA-148/152 family in non-small-cell lung cancer (NSCLC): A systematic review and meta-analysis.

Cheng L, Li Q, Tan B, Ma D, Du G Medicine (Baltimore). 2022; 100(48):e28061.

PMID: 35049226 PMC: 9191337. DOI: 10.1097/MD.0000000000028061.


miR-148a, miR-152 and miR-200b promote prostate cancer metastasis by targeting DNMT1 and PTEN expression.

Gurbuz V, Sozen S, Bilen C, Konac E Oncol Lett. 2021; 22(5):805.

PMID: 34630712 PMC: 8488332. DOI: 10.3892/ol.2021.13066.


Autophagic Inhibition of Caveolin-1 by Compound L. Activates Ubiquitination and Proteasome Degradation of β-catenin to Suppress Metastasis of Hepatitis B-Associated Hepatocellular Carcinoma.

Huang D, Yang B, Yao Y, Liao M, Zhang Y, Zeng Y Front Pharmacol. 2021; 12:659325.

PMID: 34168559 PMC: 8217966. DOI: 10.3389/fphar.2021.659325.


References
1.
Wu R, Li X, Schonthal A . Transcriptional activation of p21WAF1 by PTEN/MMAC1 tumor suppressor. Mol Cell Biochem. 2000; 203(1-2):59-71. DOI: 10.1023/a:1007024624967. View

2.
Tiollais P, Pourcel C, Dejean A . The hepatitis B virus. Nature. 1985; 317(6037):489-95. DOI: 10.1038/317489a0. View

3.
Calin G, Ferracin M, Cimmino A, Di Leva G, Shimizu M, E Wojcik S . A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005; 353(17):1793-801. DOI: 10.1056/NEJMoa050995. View

4.
Lian Z, Pan J, Liu J, Zhang S, Zhu M, Arbuthnot P . The translation initiation factor, hu-Sui1 may be a target of hepatitis B X antigen in hepatocarcinogenesis. Oncogene. 1999; 18(9):1677-87. DOI: 10.1038/sj.onc.1202470. View

5.
Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu C . Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 2007; 67(13):6092-9. DOI: 10.1158/0008-5472.CAN-06-4607. View